Drug intelligence / Profile preview

USP501

Development stage: Preclinical
Lead developer: Uscare Pharm

Overview

USP501 is a preclinical-stage product candidate being developed by the South Korean company Uscare Pharm for the treatment of facial wrinkles. It is categorized under the company's Product Innovation pipeline segment. As of 2024, the asset is in the early non-clinical phase of development. While the specific pharmacological details, such as its molecular target or modality, are not yet public, the program represents Uscare Pharm's efforts in the aesthetic dermatology space.

Beyond the preview

Go deeper on USP501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USP501.

Explore the full profile